Rep. Jim Struzzi filed two pieces of legislation which would regulate the production and sale of kratom and CBD products in Pennsylvania.
House Resolution 459 would encourage the U.S. Food and Drug Administration (FDA) to provide guidelines to the Commonwealth regarding CBD and the proliferation of CBD products. Currently, due to a lack of FDA oversight, there are no quality standards for CBD products and little consistency in the market.
“Consumers need these protections in place to ensure they are getting what they pay for,” said Struzzi. “These standards will provide retailers with the ability to properly market their CBD, and consumers with the assurance that they are buying a safe and effective product.”
House Resolution 460 would encourage the FDA to provide guidelines to over-the-counter sales of kratom. Kratom has come under scrutiny by both the FDA and the U.S. Drug Enforcement Administration, but actions to ban the substance have been withdrawn following significant opposition from the public.
“Kratom is a substance that has helped many people overcome opioid addiction, but can also be dangerous and deadly if abused,” Struzzi continued. “We need guidance and regulations governing its use so that those who do need it can get access without risking harm to others. This could save lives and help others in need.”